Clinical Trial Update: Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) [Phase 2]

View source ↗

Summary

The ACTION Phase 2 trial evaluating cabozantinib in hepatocellular carcinoma has completed, with results posted on 2025-03-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-30